Anti-tumoral effects of low molecular weight heparins: A focus on the treatment of esophageal cancer

被引：24

作者：

Javadinia, Seyed Alireza ^{[1
]}

Gholami, Arezoo ^{[1
]}

Mashhad, Mona Joudi ^{[2
]}

Ferns, Gordon A. ^{[3
]}

Shahidsales, Soodabeh ^{[2
]}

Avan, Amir ^{[4
]}

Kermani, Ali Taghizadeh ^{[5
]}

机构：

[1] Mashhad Univ Med Sci, Student Res Comm, Mashhad, Iran

[2] Mashhad Univ Med Sci, Canc Res Ctr, Mashhad, Iran

[3] Brighton & Sussex Med Sch, Div Med Educ, Dept Med Educ, Brighton, E Sussex, England

[4] Mashhad Univ Med Sci, Metab Syndrome Res Ctr, Mashhad, Iran

[5] Mashhad Univ Med Sci, Surg Oncol Res Ctr, Mashhad, Iran

来源：

JOURNAL OF CELLULAR PHYSIOLOGY | 2018年 / 233卷 / 10期

关键词：

anti-tumoral effects; esophageal cancer; low molecular weight heparin; LMWH; DEPENDENT KINASE INHIBITORS; VENOUS THROMBOEMBOLISM; BREAST-CANCER; TRANSCRIPTION FACTOR; SURVIVAL; METASTASIS; PLATELETS; PROLIFERATION; ANGIOGENESIS; PREVENTION;

D O I：

10.1002/jcp.26613

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Esophageal cancer is one of the most prevalent types of cancer globally. With current treatment options, the survival is poor, and there are ongoing efforts to find new and more efficient therapeutic approaches. There are several reports on the anti-tumoral effects of low-molecular-weight heparins (LMWH). We have assessed the possible survival benefits and underlying mechanisms of LMWHs in malignancies with a focus on esophageal cancer. We conclude that the effects of LMWHs on survival of cancer patients is probably due to a combination of direct anti-tumoral, anti-angiogenic, and immunomodulatory effects and indirect effects on the coagulation system.

引用

页码：6523 / 6529

页数：7

共 76 条

[1]

Abu Arab W, 2011, CAN J PHYSIOL PHARM, V89, P705, DOI [10.1139/Y11-068, 10.1139/y11-068]

[2] Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer [J].

Agnelli, Giancarlo ;

George, Daniel J. ;

Kakkar, Ajay K. ;

Fisher, William ;

Lassen, Michael R. ;

Mismetti, Patrick ;

Mouret, Patrick ;

Chaudhari, Umesh ;

Lawson, Francesca ;

Turpie, Alexander G. G. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (07) :601-609

[3] Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study [J].

Agnelli, Giancarlo ;

Gussoni, Gualberto ;

Bianchini, Carlo ;

Verso, Melina ;

Mandala, Mario ;

Cavanna, Luigi ;

Barni, Sandra ;

Labianca, Roberto ;

Buzzi, Franco ;

Scambia, Giovanni ;

Passalacqua, Rodolfo ;

Ricci, Sergio ;

Gasparini, Giampietro ;

Lorusso, Vito ;

Bonizzoni, Erminio ;

Tonato, Maurizio .

LANCET ONCOLOGY, 2009, 10 (10) :943-949

[4] Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation [J].

Akl, E. A. ;

van Doormaal, F. F. ;

Barba, M. ;

Kamath, G. ;

Kim, S. Y. ;

Kuipers, S. ;

Middeldorp, S. ;

Yosuico, V ;

Dickinson, H. O. ;

H J, Schuenemann .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (03)

[5] Preliminary safety evaluation of a taurocholate-conjugated low-molecular-weight heparin derivative (LHT7): a potent angiogenesis inhibitor [J].

Alam, Farzana ;

Chung, Seung Woo ;

Hwang, Seung Rim ;

Kim, Ji-young ;

Park, Jooho ;

Moon, Hyun Tae ;

Byun, Youngro .

JOURNAL OF APPLIED TOXICOLOGY, 2015, 35 (01) :104-115

[6]

[Anonymous], DIFFERENTIATION LOWM

[7]

[Anonymous], WORLD CANC REPORT

[8]

[Anonymous], ACR 101 ANN M WASH D

[9]

[Anonymous], IARC CANC BASE

[10]

[Anonymous], INT J ORAL MAXILLOFA

← 1 2 3 4 5 6 7 8 →